Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report

Background: Patients with different molecular subtypes of breast cancers have different recurrence risks and prognoses. Clinical support and evidence to guide management are absent for patients with breast cancer coexisting with HER-2 amplification and EGFR mutations.Case presentation: We report a c...

Full description

Bibliographic Details
Main Authors: Wei Jing, Jie-Tao Ma, Cheng-Bo Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
breast cancer
lung metastasis
EGFR mutation
HER-2 amplification
molecular targeted therapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00771/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00771/full

Similar Items